Skip to main content
OpenTrials

Clinical trial condition

Recurrence

Explore clinical trials studying Recurrence. Study availability and eligibility vary by location and protocol.

2,312 public trials 521 recruiting studies
Refine in advanced search Browse all conditions

Recurrence trial results

Completed

Open-label Study of IMGN779 in Adult Patients With Relapsed/Refractory CD33-positive Acute Myeloid Leukemia

NCT02674763

Conditions
Acute Myeloid Leukemia, Disease Attributes, Hematologic Diseases, +9 more
Locations
  • Comprehensive Cancer Center (UAB CCC) Birmingham, Alabama, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • New Mexico Cancer Care Alliance Albuquerque, New Mexico, United States
  • Roswell Park Cancer Institute Buffalo, New York, United States
View Trial Details
Completed

Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma

NCT00169208

Conditions
Disease Attributes, Follicular Lymphoma, Hemic and Lymphatic Diseases, +12 more
Locations
  • Service de médecine D - Maladies du Sang CHU Angers Angers, France
  • Service d'Hématologie Hôpital Jean Minjoz Besançon, France
  • Hôpital Henri Mondor Créteil, France
  • Hôpital A. Michallon BP 217X Grenoble, France
View all 16 locations
View Trial Details
Completed

Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma

NCT00932698

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +17 more
Locations
  • H. Lee Moffitt Cancer Center Tampa, Florida, United States
  • Emory University Atlanta, Georgia, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States
View Trial Details
Completed

Fosfomycin Versus Meropenem or Ceftriaxone in Bacteriemic Infections Caused by Multidrug Resistance in E.Coli

NCT02142751

Conditions
Bacteremia, Bacterial Infections, Bacterial Infections and Mycoses, +18 more
Locations
  • Hospital Mutua de Terrassa Terrassa, Barcelona, Spain
  • Hospital Universitario de Gran Canaria Dr. Negrín Las Palmas de Gran Canaria, Gran Canarias, Spain
  • Hospital Arnau de Vilanova Vilanova, Lleida, Spain
  • Hospital Clínico Universitario Virgen de la Arrixaca El Palmar, Murcia, Spain
View all 22 locations
View Trial Details
Completed

Safety and Dose Determining Multi-dose Study of BT062 in Patients With Relapsed or Refractory Multiple Myeloma

NCT01001442

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Emory University Winship Cancer Institute Atlanta, Georgia, United States
  • The University of Chicago Chicago, Illinois, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Roswell Park Cancer Institute Buffalo, New York, United States
View Trial Details

Related conditions